{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:39:34Z","timestamp":1790015974454,"version":"4.0.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011697","name":"Conseil R\u00e9gional de Bretagne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011697","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013465","name":"AFM-Telethon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-17-CE18-0015\\u201303"],"award-info":[{"award-number":["ANR-17-CE18-0015\\u201303"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-CE18-0013\\u201301"],"award-info":[{"award-number":["ANR-23-CE18-0013\\u201301"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004584","name":"Conseil R\u00e9gional de Bretagne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004584","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejpb.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T18:46:00Z","timestamp":1701542760000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Mucoactive drugs and multiple applications in pulmonary disease therapy"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0521-9880","authenticated-orcid":false,"given":"Alexis","family":"Hocquigny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Hugerot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosy","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanguy","family":"Haute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Cogulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-6395","authenticated-orcid":false,"given":"Tristan","family":"Montier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.12.001_b0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201802-0245OC","article-title":"An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases","volume":"199","author":"Ehre","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejpb.2023.12.001_b0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.chest.2017.11.008","article-title":"Mucins, Mucus, and Goblet Cells","volume":"154","author":"Ma","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2023.12.001_b0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-018-0393-7","article-title":"A revised airway epithelial hierarchy includes CFTR-expressing ionocytes","volume":"560","author":"Montoro","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2023.12.001_b0020","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1513\/AnnalsATS.201802-128AW","article-title":"Airway Epithelial Differentiation and Mucociliary Clearance","volume":"15","author":"Whitsett","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ejpb.2023.12.001_b0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1469-7580.2002.00098.x","article-title":"Regulation of the depth and composition of airway surface liquid","volume":"201","author":"Widdicombe","year":"2002","journal-title":"J Anat"},{"key":"10.1016\/j.ejpb.2023.12.001_b0030","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1152\/physrev.00004.2021","article-title":"Physiology and pathophysiology of human airway mucus","volume":"102","author":"Hill","year":"2022","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ejpb.2023.12.001_b0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev.physiol.70.113006.100702","article-title":"Structure and function of the polymeric mucins in airways mucus","volume":"70","author":"Thornton","year":"2008","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.ejpb.2023.12.001_b0040","first-page":"675","article-title":"Mucus","volume":"9","author":"Meldrum","year":"2021","journal-title":"Microbiomes and Pulmonary Disease. Biomedicines"},{"key":"10.1016\/j.ejpb.2023.12.001_b0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2213-0802-2-6","article-title":"Secretion properties, clearance, and therapy in airway disease","volume":"2","author":"Rubin","year":"2014","journal-title":"Transl Respir Med"},{"key":"10.1016\/j.ejpb.2023.12.001_b0050","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.4187\/respcare.07521176","article-title":"Mucoactive Agents for Airway Mucus Hypersecretory Diseases","volume":"52","author":"Rogers","year":"2007","journal-title":"Respir Care"},{"key":"10.1016\/j.ejpb.2023.12.001_b0055","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/biot.201400841","article-title":"Synthetic vectors for gene delivery: An overview of their evolution depending on routes of administration","volume":"10","author":"Belmadi","year":"2015","journal-title":"Biotechnol J"},{"key":"10.1016\/j.ejpb.2023.12.001_b0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.addr.2020.07.006","article-title":"Emerging trends in inhaled drug delivery","volume":"157","author":"Hickey","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ejpb.2023.12.001_b0065","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.apsb.2019.10.002","article-title":"Comparative study of mucoadhesive and mucus-penetrative nanoparticles based on phospholipid complex to overcome the mucus barrier for inhaled delivery of baicalein","volume":"10","author":"Dong","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ejpb.2023.12.001_b0070","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1183\/09059180.00003510","article-title":"Mucoactive drugs","volume":"19","author":"Balsamo","year":"2010","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ejpb.2023.12.001_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.544826","article-title":"Airway Clearance Techniques: The Right Choice for the Right Patient","volume":"8","author":"Belli","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.ejpb.2023.12.001_b0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/resp.13459","article-title":"Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis","volume":"24","author":"O\u2019Neill","year":"2019","journal-title":"Respirology"},{"key":"10.1016\/j.ejpb.2023.12.001_b0085","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4187\/respcare.04087","article-title":"Aerosol Medications for Treatment of Mucus Clearance Disorders","volume":"60","author":"Rubin","year":"2015","journal-title":"Respir Care"},{"key":"10.1016\/j.ejpb.2023.12.001_b0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"354","author":"Donaldson","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejpb.2023.12.001_b0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1586\/ers.12.72","article-title":"Effect of inhaled dry powder mannitol on mucus and its clearance","volume":"7","author":"Daviskas","year":"2013","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.ejpb.2023.12.001_b0100","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1378\/chest.107.3.747","article-title":"Effects of guaifenesin on nasal mucociliary clearance and ciliary beat frequency in healthy volunteers","volume":"107","author":"Sisson","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2023.12.001_b0105","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.pupt.2007.12.003","article-title":"Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3","volume":"21","author":"Kellerman","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ejpb.2023.12.001_b0110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2012.11.034","article-title":"Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis","volume":"162","author":"Moss","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.ejpb.2023.12.001_b0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1164\/ajrccm.154.1.8680683","article-title":"Acute safety and effects on mucociliary clearance of aerosolized uridine 5\u2019-triphosphate +\/- amiloride in normal human adults","volume":"154","author":"Olivier","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejpb.2023.12.001_bib436","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1183\/09059180.00003510","article-title":"Mucoactive drugs","volume":"19","author":"Balsamo","year":"2010","journal-title":"Eur Respir Rev Off J Eur Respir Soc"},{"key":"10.1016\/j.ejpb.2023.12.001_b0120","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1165\/rcmb.2008-0037OC","article-title":"Salmeterol restores secretory functions in cystic fibrosis airway submucosal gland serous cells","volume":"40","author":"Delavoie","year":"2009","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ejpb.2023.12.001_b0125","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1378\/chest.09-1214","article-title":"Safety of long-acting beta-agonists: are new data really required?","volume":"136","author":"Sears","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2023.12.001_b0130","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4187\/respcare.06051","article-title":"Clinical Pharmacology of Bronchodilator Medications","volume":"63","author":"Williams","year":"2018","journal-title":"Respir Care"},{"key":"10.1016\/j.ejpb.2023.12.001_b0135","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1378\/chest.121.3.702","article-title":"Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD","volume":"121","author":"Wolkove","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2023.12.001_b0140","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/17425255.4.8.1119","article-title":"Ambroxol in the 21st century: pharmacological and clinical update","volume":"4","author":"Malerba","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ejpb.2023.12.001_b0145","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1378\/chest.13-2609","article-title":"Secretory hyperresponsiveness and pulmonary mucus hypersecretion","volume":"146","author":"Rubin","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2023.12.001_b0150","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2010.05.045","article-title":"Carbocisteine normalizes the viscous property of mucus through regulation of fucosylated and sialylated sugar chain on airway mucins","volume":"641","author":"Ishibashi","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ejpb.2023.12.001_b0155","first-page":"81","article-title":"Randoux A","volume":"26","author":"Havez","year":"1970","journal-title":"Poumon Coeur"},{"key":"10.1016\/j.ejpb.2023.12.001_b0160","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000185494","article-title":"S-CMC-Lys protective effects on human respiratory cells during oxidative stress","volume":"22","author":"Garavaglia","year":"2008","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"10.1016\/j.ejpb.2023.12.001_b0165","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.2147\/DDDT.S198874","article-title":"Carbocisteine inhibits the expression of Muc5b in COPD mouse model","volume":"13","author":"Song","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ejpb.2023.12.001_b0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00109-005-0720-y","article-title":"S-CMC-Lys-dependent stimulation of electrogenic glutathione secretion by human respiratory epithelium","volume":"84","author":"Guizzardi","year":"2006","journal-title":"J Mol Med Berl Ger"},{"key":"10.1016\/j.ejpb.2023.12.001_b0175","unstructured":"Pulmonary and Critical Care Pharmacology and Therapeutics. McGraw-Hill Professional Publishing; 1996."},{"key":"10.1016\/j.ejpb.2023.12.001_b0180","first-page":"295","article-title":"Peripheral airways mucus clearance in stable asthma is improved by oral corticosteroid therapy","volume":"20","author":"Agnew","year":"1984","journal-title":"Bull Eur Physiopathol Respir"},{"key":"10.1016\/j.ejpb.2023.12.001_b0185","doi-asserted-by":"crossref","unstructured":"Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004;125:52S-60S; quiz 60S-61S. https:\/\/doi.org\/10.1378\/chest.125.2_suppl.52s.","DOI":"10.1378\/chest.125.2_suppl.52S"},{"key":"10.1016\/j.ejpb.2023.12.001_b0190","series-title":"Mucolytic Medications","author":"Gupta","year":"2022"},{"key":"10.1016\/j.ejpb.2023.12.001_b0195","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/cells10113107","article-title":"Apparent Yield Stress of Sputum as a Relevant Biomarker in Cystic Fibrosis","volume":"10","author":"Ghanem","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejpb.2023.12.001_b0200","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4187\/respcare.07520859","article-title":"Mucolytics, Expectorants, and Mucokinetic Medications","volume":"52","author":"Rubin","year":"2007","journal-title":"Respir Care"},{"key":"10.1016\/j.ejpb.2023.12.001_b0205","first-page":"425","article-title":"Role of N-acetylcysteine in the management of COPD","volume":"1","author":"Sadowska","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejpb.2023.12.001_b0210","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/antiox10060967","article-title":"N-Acetylcysteine (NAC): Impacts on Human Health","volume":"10","author":"Ten\u00f3rio","year":"2021","journal-title":"Antioxid Basel Switz"},{"key":"10.1016\/j.ejpb.2023.12.001_b0215","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12931-019-1078-y","article-title":"Efficacy and safety profile of mucolytic\/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine","volume":"20","author":"Rogliani","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.ejpb.2023.12.001_b0220","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.3889\/oamjms.2019.697","article-title":"Effects of a Long-Term Use of Carbocysteine on Frequency and Duration of Exacerbations in Patients with Bronchiectasis","volume":"7","author":"Minov","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"10.1016\/j.ejpb.2023.12.001_b0225","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2006.12.006","article-title":"An overview of erdosteine antioxidant activity in experimental research","volume":"55","author":"Moretti","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejpb.2023.12.001_b0230","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.00018508","article-title":"Effect of fudosteine on mucin production","volume":"32","author":"Rhee","year":"2008","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"10.1016\/j.ejpb.2023.12.001_b0235","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1007\/s00408-007-9065-3","article-title":"Erdosteine: antitussive and anti-inflammatory effects","volume":"186","author":"Dal Negro","year":"2008","journal-title":"Lung"},{"key":"10.1016\/j.ejpb.2023.12.001_b0240","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001127.pub4","article-title":"Dornase alfa for cystic fibrosis","author":"Yang","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejpb.2023.12.001_b0245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13052-022-01331-5","article-title":"Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index","volume":"48","author":"Terlizzi","year":"2022","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.ejpb.2023.12.001_b0250","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ppul.21388","article-title":"Clinical Use of Dornase Alfa Is Associated with a Slower Rate of FEV1 Decline in Cystic Fibrosis","volume":"46","author":"Konstan","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ejpb.2023.12.001_b0255","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1099-0496(199901)27:1<3::AID-PPUL2>3.0.CO;2-A","article-title":"Who will benefit from DNase?","volume":"27","author":"Rubin","year":"1999","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ejpb.2023.12.001_b0260","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0012-3692(15)37320-7","article-title":"Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro","volume":"130","author":"Rubin","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2023.12.001_b0265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14712598.2012.634793","article-title":"Thymosin \u03b24: a multi-functional regenerative peptide. Basic properties and clinical applications","volume":"12","author":"Goldstein","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ejpb.2023.12.001_b0270","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1415.008","article-title":"Thymosin beta4: actin regulation and more","volume":"1112","author":"Yarmola","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejpb.2023.12.001_b0275","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14712598.2018.1459558","article-title":"Thymosin \u03b24 and the vasculature: multiple roles in development, repair and protection against disease","volume":"18","author":"Dub\u00e9","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ejpb.2023.12.001_b0280","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.8310296","article-title":"Kinetics of molecular chaperone action","volume":"263","author":"Schmid","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2023.12.001_b0285","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1126\/science.8310295","article-title":"Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin","volume":"263","author":"Vasconcellos","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2023.12.001_b0290","doi-asserted-by":"crossref","first-page":"L1240","DOI":"10.1152\/ajplung.00206.2007","article-title":"Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis","volume":"293","author":"Broughton-Head","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.ejpb.2023.12.001_b0295","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pupt.2017.10.001","article-title":"Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study","volume":"48","author":"Shute","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ejpb.2023.12.001_b0300","first-page":"799","article-title":"High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial","volume":"11","author":"Johnson","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejpb.2023.12.001_b0305","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/COPD.S8196","article-title":"Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study","volume":"4","author":"Chavannes","year":"2009","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejpb.2023.12.001_b0310","doi-asserted-by":"crossref","unstructured":"Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2021;3:CD001127. https:\/\/doi.org\/10.1002\/14651858.CD001127.pub5.","DOI":"10.1002\/14651858.CD001127.pub5"},{"key":"10.1016\/j.ejpb.2023.12.001_b0315","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.rmed.2015.09.017","article-title":"Effect of a single 1200 Mg dose of Mucinex\u00ae on mucociliary and cough clearance during an acute respiratory tract infection","volume":"109","author":"Bennett","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.ejpb.2023.12.001_b0320","first-page":"e0156999","article-title":"Mucolytic Effectiveness of Tyloxapol in Chronic Obstructive Pulmonary Disease - A Double-Blind","volume":"11","author":"Koppitz","year":"2016","journal-title":"Randomized Controlled Trial. Plos One"},{"key":"10.1016\/j.ejpb.2023.12.001_b0325","doi-asserted-by":"crossref","first-page":"1700711","DOI":"10.1183\/13993003.00711-2017","article-title":"Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study","volume":"50","author":"Dal Negro","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejpb.2023.12.001_b0330","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12931-019-1042-x","article-title":"Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial","volume":"20","author":"Qi","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.ejpb.2023.12.001_b0335","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1183\/09031936.00187510","article-title":"Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study","volume":"38","author":"Bilton","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejpb.2023.12.001_b0340","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2147\/COPD.S49307","article-title":"Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients","volume":"8","author":"De Backer","year":"2013","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejpb.2023.12.001_b0345","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40261-016-0405-z","article-title":"An Open-Label Investigation of the Pharmacokinetics and Tolerability of Oral Cysteamine in Adults with Cystic Fibrosis","volume":"36","author":"Devereux","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ejpb.2023.12.001_b0350","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1753465817710596","article-title":"Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection","volume":"11","author":"Greenwood","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.ejpb.2023.12.001_b0355","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1378\/chest.09-2017","article-title":"Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis","volume":"137","author":"Daviskas","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ejpb.2023.12.001_b0360","unstructured":"Home - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ (accessed November 23, 2022)."},{"key":"10.1016\/j.ejpb.2023.12.001_b0365","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1183\/16000617.00000315","article-title":"An official American Thoracic Society\/European Respiratory Society statement: research questions in COPD","volume":"24","author":"Celli","year":"2015","journal-title":"Eur Respir Rev off J Eur Respir Soc"},{"key":"10.1016\/j.ejpb.2023.12.001_b0370","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(17)31222-9","article-title":"Chronic obstructive pulmonary disease","volume":"389","author":"Rabe","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejpb.2023.12.001_b0375","series-title":"Chronic Obstructive Pulmonary Disease","author":"Agarwal","year":"2022"},{"key":"10.1016\/j.ejpb.2023.12.001_b0380","doi-asserted-by":"crossref","first-page":"1900164","DOI":"10.1183\/13993003.00164-2019","article-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019","volume":"53","author":"Singh","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejpb.2023.12.001_b0385","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60968-9","article-title":"Chronic obstructive pulmonary disease","volume":"379","author":"Decramer","year":"2012","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ejpb.2023.12.001_b0390","doi-asserted-by":"crossref","first-page":"00155","DOI":"10.1183\/23120541.00155-2023","article-title":"Response to endobronchial valve treatment: it\u2019s all about the target lobe","volume":"9","author":"Hartman","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ejpb.2023.12.001_b0395","first-page":"4809","article-title":"A randomized, double-blind, placebo-controlled study evaluating the efficacy of propolis and N-acetylcysteine in exacerbations of chronic obstructive pulmonary disease","volume":"26","author":"Buha","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ejpb.2023.12.001_b0400","first-page":"564","article-title":"Cystic Fibrosis","volume":"114","author":"Naehrig*","year":"2017","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"10.1016\/j.ejpb.2023.12.001_b0405","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jpeds.2012.10.008","article-title":"Evolution of pancreatic function during the first year in infants with cystic fibrosis","volume":"162","author":"O\u2019Sullivan","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.ejpb.2023.12.001_b0410","first-page":"1891","volume":"373","author":"O\u2019Sullivan","year":"2009","journal-title":"Cystic Fibrosis. Lancet Lond Engl"},{"key":"10.1016\/j.ejpb.2023.12.001_b0415","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1183\/09059180.00008512","article-title":"Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation","volume":"22","author":"Sermet-Gaudelus","year":"2013","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ejpb.2023.12.001_b0420","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejpb.2023.12.001_b0425","first-page":"828","article-title":"Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del\/Unknown Genotype","volume":"10","author":"Comegna","year":"2021","journal-title":"Antibiot Basel Switz"},{"key":"10.1016\/j.ejpb.2023.12.001_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122491","article-title":"Gene transfection using branched cationic amphiphilic compounds for an aerosol administration in cystic fibrosis context","volume":"631","author":"Ghanem","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejpb.2023.12.001_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118500","article-title":"Antibacterial and transfection activities of nebulized formulations incorporating long n-alkyl chain silver N-heterocyclic carbene complexes","volume":"567","author":"Mottais","year":"2019","journal-title":"Int J Pharm"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123003211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123003211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:10:42Z","timestamp":1778559042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123003211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":88,"alternative-id":["S0939641123003211"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.12.001","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mucoactive drugs and multiple applications in pulmonary disease therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}